111536
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
特立妥昔单抗治疗儿童 IgA 肾病及 IgA 血管炎相关性肾炎的疗效和安全性：一项回顾性单中心研究
Authors Zhou L, Yang F, Han Y, Yang Y, Wu SY , Zhang Y, Zhou J
Received 4 September 2025
Accepted for publication 28 November 2025
Published 16 December 2025 Volume 2025:19 Pages 11207—11216
DOI https://doi.org/10.2147/DDDT.S565279
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Tuo Deng
Lanqi Zhou, Fengjie Yang, Yanxinli Han, Yuan Yang, Shi Yi Wu, Yu Zhang, Jianhua Zhou
Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China
Correspondence: Jianhua Zhou, Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China, Email jhzhou99@qq.com
Background: Childhood IgA nephropathy (IgAN) and IgA Vasculitis-associated nephritis (IgAVN) are same in pathogenesis and still a challenge to pediatricians.
Purpose: To evaluate the efficacy and safety of Telitacicept in pediatric patients with IgAN or IgAVN.
Patients and Methods: This was a retrospective single-centre study of pediatric IgAN or IgAVN with urine protein-to-creatinine ratio (UPCR) over 500 μg/mg who were treated with subcutaneous administration of Telitacicept and followed for at least 6 months. The effects on induction of remission and side effects were evaluated.
Results: 13 pediatric patients including 7 with IgAN and 6 with IgAVN were enrolled in the study. After 6-month treatment, 6 of 13 (46.15%) patients achieved remission, 4 (30.77%) patient achieved complete remission. The median percent reduction in UPCR was 90.74% (84.38%, 94.76%). The median percent reduction in urine red blood cells count was 96.21% (75.33%, 98.99%). Compared with baseline, serum albumin increased significantly [P < 0.001, 95% CI (− 10.30, − 4.04)], and estimated glomerular filtration rate (eGFR) remained stable and within the normal range. Significant reductions were observed in levels of IgA [P < 0.001; 95% CI (1.15, 2.49)], IgM [P = 0.002; 95% CI (0.53, 1.08)], as well as CD19+ lymphocytes [P = 0.012; 95% CI (6.63, 34.67)]. The average follow-up was 6.5 ± 0.8 months, 5 patients achieved glucocorticoid discontinuation. No severe adverse events were observed.
Conclusion: Telitacicept was safe in pediatric IgAN/IgAVN patients and could significantly induce renal remission through reducing proteinuria and hematuria.
Keywords: telitacicept, IgA nephropathy, IgA vasculitis-associated nephritis, pediatric, efficacy, safety
Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China
Correspondence: Jianhua Zhou, Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China, Email jhzhou99@qq.com
Background: Childhood IgA nephropathy (IgAN) and IgA Vasculitis-associated nephritis (IgAVN) are same in pathogenesis and still a challenge to pediatricians.
Purpose: To evaluate the efficacy and safety of Telitacicept in pediatric patients with IgAN or IgAVN.
Patients and Methods: This was a retrospective single-centre study of pediatric IgAN or IgAVN with urine protein-to-creatinine ratio (UPCR) over 500 μg/mg who were treated with subcutaneous administration of Telitacicept and followed for at least 6 months. The effects on induction of remission and side effects were evaluated.
Results: 13 pediatric patients including 7 with IgAN and 6 with IgAVN were enrolled in the study. After 6-month treatment, 6 of 13 (46.15%) patients achieved remission, 4 (30.77%) patient achieved complete remission. The median percent reduction in UPCR was 90.74% (84.38%, 94.76%). The median percent reduction in urine red blood cells count was 96.21% (75.33%, 98.99%). Compared with baseline, serum albumin increased significantly [P < 0.001, 95% CI (− 10.30, − 4.04)], and estimated glomerular filtration rate (eGFR) remained stable and within the normal range. Significant reductions were observed in levels of IgA [P < 0.001; 95% CI (1.15, 2.49)], IgM [P = 0.002; 95% CI (0.53, 1.08)], as well as CD19+ lymphocytes [P = 0.012; 95% CI (6.63, 34.67)]. The average follow-up was 6.5 ± 0.8 months, 5 patients achieved glucocorticoid discontinuation. No severe adverse events were observed.
Conclusion: Telitacicept was safe in pediatric IgAN/IgAVN patients and could significantly induce renal remission through reducing proteinuria and hematuria.
Keywords: telitacicept, IgA nephropathy, IgA vasculitis-associated nephritis, pediatric, efficacy, safety